Gamida Cell Ltd. (GMDA) Misses Q2 EPS by 2c

Gamida Cell Ltd. (NASDAQ: GMDA) reported Q2 EPS of ($0.31), $0.02 worse than the analyst estimate of ($0.29).

Finished second quarter of 2022 with $55.1 million in cash; sufficient funding for the company’s operations into mid-2023, excluding the cost of commercializing omidubicel.

For earnings history and earnings-related data on Gamida Cell Ltd. (GMDA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c